Genmab A/S Share Price Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.08 USD | -0.63% |
|
-0.28% | -18.57% |
| Market Cap | 9.94TCr 1.54TCr 1.33TCr 1.23TCr 1.15TCr 2.15TCr 1,46400Cr 2.18TCr 14TCr 5.64TCr 71TCr 5.78TCr 5.66TCr 2,46700Cr | P/E Ratio 2026 * |
21.4x | P/E Ratio 2027 * | 14.9x |
|---|---|---|---|---|---|
| Enterprise Value | 12TCr 1.84TCr 1.59TCr 1.47TCr 1.37TCr 2.57TCr 1,75100Cr 2.61TCr 17TCr 6.75TCr 85TCr 6.91TCr 6.77TCr 2,95100Cr | EV / Sales 2026 * |
4.3x | EV / Sales 2027 * | 3.45x |
| Free-Float |
95.41% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab A/S
| 1 day | -0.63% | ||
| 1 week | -0.28% | ||
| Current month | -4.75% | ||
| 1 month | -7.42% | ||
| 3 months | -5.61% | ||
| 6 months | -19.90% | ||
| Current year | -18.57% |
| 1 week | 24.46 |  | 25.38 |
| 1 month | 23.62 | | 27.36 |
| Current year | 23.62 | | 35.43 |
| 1 year | 20.22 | | 35.43 |
| 3 years | 17.24 | | 42.72 |
| 5 years | 17.24 | | 49.07 |
| 10 years | 12.1 | | 49.07 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/06/2010 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 01/03/2020 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 16/08/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 01/11/2003 | |
| Director/Board Member | 58 | 01/01/2015 | |
| Director/Board Member | 75 | 01/01/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.63% | -0.28% | - | - | 1.54TCr | |
| +1.03% | +2.30% | +54.92% | +111.78% | 5.64TCr | |
| +2.72% | +3.26% | +47.26% | +47.26% | 4.45TCr | |
| +1.12% | +2.79% | -13.71% | -17.53% | 2.29TCr | |
| +1.17% | +3.85% | +1.00% | +401.79% | 2.12TCr | |
| +3.81% | -5.07% | +12.00% | -29.52% | 1.64TCr | |
| -0.69% | +0.82% | +27.17% | +178.31% | 1.34TCr | |
| +5.27% | +5.54% | +14.25% | - | 1.24TCr | |
| +1.61% | +1.28% | +92.88% | +215.31% | 1.12TCr | |
| +1.37% | -1.28% | +61.76% | +80.92% | 1.11TCr | |
| Average | +1.68% | +1.70% | +33.06% | +123.54% | 2.33TCr | |
| Weighted average by Cap. | +1.65% | +2.18% | +35.18% | +110.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.76TCr 428.39Cr 370Cr 340.96Cr 319.15Cr 598.11Cr 41TCr 607.37Cr 4.03TCr 1.57TCr 20TCr 1.61TCr 1.57TCr 69TCr | 3.24TCr 502.3Cr 433.83Cr 399.78Cr 374.21Cr 701.3Cr 48TCr 712.16Cr 4.72TCr 1.84TCr 23TCr 1.89TCr 1.84TCr 80TCr |
| Net income | 471.21Cr 73Cr 63Cr 58Cr 54Cr 101.95Cr 6.94TCr 103.53Cr 686.21Cr 267.55Cr 3.38TCr 274.04Cr 268.21Cr 12TCr | 701.9Cr 108.77Cr 94Cr 87Cr 81Cr 151.86Cr 10TCr 154.21Cr 1.02TCr 398.53Cr 5.03TCr 408.2Cr 399.51Cr 17TCr |
| Net Debt | 1.95TCr 302.07Cr 260.9Cr 240.41Cr 225.04Cr 421.74Cr 29TCr 428.27Cr 2.84TCr 1.11TCr 14TCr 1.13TCr 1.11TCr 48TCr | 1.25TCr 193.28Cr 166.94Cr 153.83Cr 143.99Cr 269.85Cr 18TCr 274.03Cr 1.82TCr 708.19Cr 8.94TCr 725.38Cr 709.93Cr 31TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/26/12 | 25.08 $ | -0.63% | 11,13,721 |
| 11/26/11 | 25.24 $ | +3.06% | 11,73,452 |
| 10/26/10 | 24.49 $ | -2.43% | 8,76,185 |
| 09/26/09 | 25.10 $ | +1.21% | 13,29,445 |
| 08/26/08 | 24.80 $ | -1.39% | 14,35,931 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
